Latest news with #MelissaPalmer
CBC
08-04-2025
- Automotive
- CBC
London woman calls for traffic light at crosswalk by Children's Museum, amid safety concerns
A London mom is calling on the city to improve safety at a pedestrian crosswalk near the Children's Museum that's surrounded by heavy traffic, construction and drivers who don't follow the rules, and she fears it could result in someone getting seriously hurt. Melissa Palmer frequently takes her sons to the new museum in Old East Village and says she's had a few close calls at the intersection of Dundas Street and Kellogg Lane, with vehicles plowing through and ignoring flashing lights that tell them to stop for pedestrians. "Every single time I've tried to use these crosswalks, I've had at least one vehicle go through the crosswalk while the lights are active," said Palmer. "My primary concern is that as both foot traffic and vehicle traffic increases in this area, there is a risk to the public, especially with so many young children not being able to safely cross the road." The crosswalk is adjacent to an extra parking lot for museum visitors and has a button that activates flashing lights on both sides, with clearly marked signs directing vehicles to stop for crossing pedestrians. But the narrow road curves and is down to one lane on each side filled with construction pylons for the East London Bus Rapid Transit project. Palmer wants the city to add a traffic light to the walkway to ensure vehicles actually stop. Crossing the road in its current state is dangerous, especially for families with young kids and strollers, she said. "There needs to be some sort of light that's in the view of the drivers more easily," she said. "Currently, the lights are only on the sides of the street and they're quite difficult to see, especially if the sun is at an eye level where it makes it difficult to view the sides of the road." In January, the museum opened up at its new location at 100 Kellogg Lane. It's part of a massive entertainment complex that houses merchants, an indoor play park, eateries, and will soon be home to a new Hard Rock Hotel in May. City says it's working to improve crosswalk Emmet Fishersteed works near the museum and uses the crosswalk daily and said she's had a few encounters where vehicles didn't stop for her as she tried to cross. "The sign there that says 'Stop for pedestrians' is pretty in your face but the lights during the day aren't super visible," she said. "Sometimes I'll make eye contact with a driver telling them the lights are going and then they realize they have to stop, so I feel it's not super obvious." Palmer addressed her concerns in a letter to Mayor Josh Morgan and London police, asking them to drive around the area on a busy weekend and witness firsthand the safety issues at the crosswalk. In response, the city said it's aware of the concern and is working on ways to provide tips to drivers on how to travel safely in the area, including email and social media blasts. In a statement to CBC News, Jennie Dann, the city's head of construction and infrastructure, said construction for the crosswalk is expected to wrap up by the summer and the city is working closely with the contractor to improve the road for pedestrians. "This is a constrained area with significant work to be completed. Several measures have already been taken to address this including line painting, and placing advance warning signage on both sides of Dundas Street to alert drivers of the pedestrian crosswalk at Kellogg Lane," she said. Signs are also posted around the construction zone to help pedestrians navigate safely, said Dann, adding that safety measures are adjusted as needed. Palmer said she anticipates more visitors to the area during the summer and wants the city to address these issues to ensure a safe experience for everyone.
Yahoo
06-02-2025
- Business
- Yahoo
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today positive results from its preclinical studies with SMC Laboratories ('SMC'). The three studies demonstrated statistically significant reversal of liver fibrosis with leronlimab monotherapy (compared to an isotype IgG4 control arm with p-values across all 3 studies < 0.01). The first two studies, completed in late 2024, evaluated leronlimab in the STAM™ model of metabolic dysfunction associated steatohepatitis (MASH) with fibrosis in mice who received a single dose of Streptozocin at birth and were then fed a high fat diet from weeks four to twelve. The third study, concluded in January 2025, evaluated reversal of liver fibrosis in mice who received carbon tetrachloride, a liver fibrosis-inducing agent, from birth to sacrifice at day 35. 'The management of patients with advanced liver fibrosis due to a variety of etiologies is an area of enormous unmet need in the field of hepatology. The results of these three preclinical studies support both the biologic activity and potential clinical benefit of leronlimab's ability to bind to CCR5 receptors on hepatic stellate cells, leading to a reversal of established liver fibrosis,' said Melissa Palmer, MD FAASLD, the Company's Lead Consultant in Hepatology. Dr. Jacob Lalezari, CEO of CytoDyn, added, 'We are very encouraged by these initial findings, which add to the growing body of evidence that leronlimab's core mechanism of action, binding to CCR5 receptors on cells, could translate into a variety of meaningful clinical benefits for patients across a number of medical conditions. As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.' CytoDyn is currently in discussions with several third parties regarding next steps in an effort to expand on these promising findings. The Company intends to explore a number of potential synergies and partnership opportunities in the coming months as it furthers its clinical development pipeline, including opportunities that might explore the potential widespread applications for leronlimab as a treatment path for fibrosis in other organs. About CytoDyn CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. About SMC Laboratories SMC Laboratories, Inc. is a CRO, with a focus on conducting the non-clinical research necessary for the drug development process. As a global consulting company that designs studies according to customer requests, it supports cutting-edge non-clinical pharmacological studies. The company owns a variety of mouse models for inflammation and fibrosis in various organs, centered on the innovative STAM™ mouse animal model of liver cancer derived from MASLD (metabolic dysfunction-associated steatotic liver disease). This patented mouse model was developed by SMC Laboratories as a worldwide-first model based on MASLD. We offer non-clinical pharmacological studies using the model mouse. Please check the company's website for further details. Note Regarding Forward-Looking Statements This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned 'Forward-Looking Statements' and in Item 1A. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments. Media Contacts CytoDyn Inc. Riyaz Lalani Gagnier Communications CytoDyn@ in to access your portfolio
